A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting where good ideas are being implemented, it encourages their wider uptake.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
Company Engagement Manager

Marijn Verhoef

Email: mverhoef@accesstomedicinefoundation.org

Marijn Verhoef is the Company Engagement Manager at the Foundation and manages the Foundation’s company engagement team. Marijn moved into this role after having worked as a Researcher on the Foundation’s research team for the Antimicrobial Resistance Benchmark. He is a pharmacist by training, holding a Master’s degree in Pharmaceutical Sciences from Utrecht University in the Netherlands, where he completed a thesis on medication-related hospital admissions. Before joining the Foundation, Marijn spent more than 5 years working in marketing and medical affairs in a multinational pharmaceutical company in roles relating to immunology and infectious diseases.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.